BIOGEN: Q3 2026 IN-PROCESS R&D CHARGE OF ABOUT $284 MLN EXPECTED TO REDUCE GAAP DILUTED EPS BY $1.65, ADJ EPS BY $1.70

Reuters · 1d ago

Please log in to view news